A meta-analysis by Wu et al. of over 200 patients with pulmonary hypertension secondary to chronic systolic heart failure reported PDE-5 inhibitors as an add-on therapy to reduce the mean PAP by 5.71 mm Hg (p < 0.05) [23]. Here, PDE5A is linked to pulmonary arterial hypertension.